人福医药：咪达唑仑注射液获法国上市许可

Core Viewpoint - The company Yichang Renfu Pharmaceutical, a subsidiary of Renfu Pharmaceutical (600079), has received approval from the French National Agency for the Safety of Medicines and Health Products for the marketing authorization of midazolam injection, which is indicated for sedation, pre-anesthesia in adults and children, and sedation in intensive care units [1] Group 1 - The approved indications for midazolam injection include sedation, pre-anesthesia in adults and children, and sedation in intensive care units [1] - The marketing authorization application was submitted in December 2023 and has now been approved, with a validity period of five years [1] - The total R&D investment for this project is approximately 8 million RMB [1] Group 2 - According to IQVIA data, the estimated annual sales for midazolam injection in the French market in 2024 is approximately 33 million USD [1]